Header

Overview :

We decided to use nanoparticles as our carrier. We then had to find which kind of nanoparticles would suit our project the best. We first thought about polymers, but we needed something that could easily be degraded. So, we decided to use gelatin. It can be specifically degraded by enzymes. What's more, we found that many different kinds of gelatin nanoparticles had been made, with various loadings, such as proteins, organic molecules or DNA. We made our gelatin nanoparticles using a modified two-step desolvation method, and loaded them with fluorescently labeled dextran and recombinant GFP. We also labeled the nanoparticles directly with a dye. In addition, all of them were biotinylated, so that they could be linked to bacteria expressing streptavidin on their surface.

Figure 1: CY5-labeling of the nanoparticles

Figure 2: Biotinylation of the loaded nanoparticles

Making nanoparticles (try 1) :

We made our gelatin nanoparticles using a modified two-step desolvation method [1]. In this method, acetone is progressively added to a gelatin solution under constant stirring. Since gelatin is not soluble in acetone, two phases start to form: the acetone-water solution (organic) and the aqueous gelatin (non organic). In order to minimize the system's energy, the gelatin struggles do reduce its surface over volume ratio, hence forming nanospheres. At the end of the reaction, the nanoparticles are stabilized by glutaraldehyde crosslinking.

Figure 3: DLS measurement of the naked nanoparticles (size distribution by intensity)

We characterized them using dynamic light scattering (DLS). This technique allows the determination of the size distribution profile of small particles in suspension. Indeed, small particles scatter light in all direction (Rayleigh scattering), but also undergo brownian motion. Hence, the intensity of the scattered light as a function of time is representative of the size of the particles. The first particles we made with this protocol have an average diameter of about 200 nm.

Figure 4: DLS measurement of the naked nanoparticles (size distribution by intensity)

Figure 5: DLS measurement of the naked nanoparticles (size distribution by volume)

Biotinylating nanoparticles :

The next step was to biotinylate our nanoparticles. Biotin is a very small vitamin (244 Da) that binds very strongly to avidin and streptavidin proteins. Biotinylation was made using activated biotin (Sulfo-NHS-LC-LC-Biotin), which binds primary amino groups (-NH2) and forms stable amide bonds. We used an ELISA-like assay to assess the biotinylation. It showed that biotin was indeed present on the nanoparticles. Classical Enzyme-Linked Immunosorbent Assay (ELISA) allows detection of an antigen using a correspondant biotinylated antibody, which in turn is detected by avidin-HRP. Since we wanted to detect directly biotin, we skipped the first part of the assay (i.e. we started directly by adding avidin-HRP). We detected HRP activity using TMB ELISA Substrate, yielding a blue color where HRP, hence biotin, has been detected. Upon addition of ELISA stop solution (2N H2SO4), the positive samples turn yellow. Quantitative data can be obtained by measuring absorbance at 412 nm with a plate reader.

Figure 6: Fluorescence measurement of the different samples used in the ELISA-like assay

Figure 7: 96 well UV-plate with ELISA-like assay. Yellow wells indicate reaction with streptavidin, i.e. presence of biotin (lines B and H)

Labeling the nanoparticles :

The biotinylated gelatin nanoparticles were labeled with an NHS-ester dye. This allowed visualisation of the nanoparticles with a confocal microscope.

Figure 8: CY5-labeled biotinylated nanoparticles

Figure 9: Negative control : biotinylated nanoparticles

We can see that the nanoparticles were successfully labeled. However, there were many clusters. Hence, a second image was taken (using a fluorescent microscope) after sonication.

Figure 10: Sonicated CY5-labeled biotinylated nanoparticles

Making nanoparticles (try 2) :

We made two new batches of gelatin nanoparticles using the same modified two-step desolvation method. This time, we loaded them with recombinant GFP (molecular weight of ~25 kDa) and FITC-labeled dextran (molecular weight of ~150 kDa). The new nanoparticles have a mean diameter of about 200 nm, as shown by the DLS measurements. We tested the loading by microscopy. Though the FITC-dextran was successfully introduced into the nanoparticles, it was not the case for the recombinant GFP. It is probably due to its smaller molecular weight, which allowed it to come out of the nanoparticles. What's more, the procedure implies incubation in acetone, which denatures proteins.

Figure 11: DLS measurments of the FITC-dextran loaded nanopartciles

Figure 12: DLS measurements of the rGFP loaded nanoparticles

Figure 13: FITC-dextran loaded nanoparticles

Making loaded nanoparticles :

The FITC-dextran-loaded nanoparticles and the rGFP-loaded nanoparticles were biotinylated using the same activated biotin as for the previous nanoparticles. Biotinylation was successful, as shown by the ELISA-like assay.

Figure 14: Fluorescence measurement of the different samples used in the ELISA-like assay with FITC-Dextran loaded nanoparticles

Figure 15: Fluorescence measurement of the different samples used in the ELISA-like assay with rGFP loaded nanoparticles

We thought about making a third batch of nanoparticles, loading them with antibodies. However, we wanted to test first whether they could survive the low pH and the acetone. We found that the low pH (2.5) didn't denature antibodies. However, the acetone does. Thus, what could be done is to chemically attach antibodies on the nanoparticles surface, as done with NHS-ester dye (see above). Something similar has been done at the National Taiwan University [2].

References :

[1] Layer-by-Layer-Coated Gelatin Nanoparticles as a Vehicle for Delivery of Natural Polyphenols,Shutava TG et al. (2009)

[2] Targeting efficiency and biodistribution of biotinylated-EGF-conjugated gelatin nanoparticles administered via aerosol delivery in nude mice with lung cancer, Tseng CL et al. (2008)